Immunic is a is a clinical-stage biopharmaceutical company developing a pipeline of potentially best-in-class, selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.
Immunic AG was founded in 2016 with headquarters in Planegg-Martinsried, Germany. Research and development activities began in September 2016 after the intellectual property rights for IMU-838 and IMU-935 were acquired from 4SC AG.
Immunic, Inc. was incorporated in Delaware. The German subsidiary, Immunic AG, is incorporated under German law with its registered office in Gräfelfing, Germany, and registered in the commercial register of the local court of Munich, Germany, under number HRB 223333.
Immunic, Inc. is headquartered in New York. Its operating subsidiary, Immunic AG, is based in Gräfelfing, Germany, where the company’s research and development activities are conducted. Additional subsidiaries are located in Halle (Saale), Germany, and Melbourne, Australia.
Immunic, Inc. began trading on The Nasdaq Stock Market under the symbol IMUX on April 15, 2019, following a stock-for-stock exchange transaction with Vital Therapies, Inc. which closed on April 12, 2019.
On January 6, 2019, Immunic AG and its former shareholders entered into an Exchange Agreement with Vital Therapies, Inc. Under this agreement, Vital Therapies changed its name to Immunic, Inc. and then acquired all of the outstanding shares of Immunic AG in exchange for newly issued shares of Immunic Inc., resulting in Immunic AG becoming a wholly-owned subsidiary. The transaction closed on April 12, 2019, and resulted in a publicly traded biopharmaceutical company focused on advancing Immunic‘s pipeline of clinical-stage and late preclinical assets.
Immunic’s fiscal year end is December 31.
The CUSIP number of the company’s common stock is 4525EP 101.
Immunic’s stock transfer agent is American Stock Transfer & Trust Company, LLC, or “AST.” AST’s address is PO Box 12893, Philadelphia, PA 19176-0893, USA. They can be reached at +1 (800) 937-5449 or +1 (718) 921-8124 or email@example.com.
Your shares of Immunic, Inc. remained outstanding; however, in connection with the transaction, Immunic, Inc. conducted a reverse stock split at a ratio of 40:1. If you have questions, you can contact Jessica Breu, Head of Investor Relations and Communications, firstname.lastname@example.org, +49 89 2080 477 09.
You can purchase or sell Immunic’s stock through any licensed brokerage firm.
Immunic does not currently pay any cash or other dividends. Management anticipates that it will retain all available funds and any future earnings, if any, for use in the operation of the business.
Immunic’s independent auditors are Baker Tilly Virchow Krause, LLP, 225 South Sixth Street, Suite 2300, Minneapolis, MN 55402-4661, USA.
To sign up for email alerts on the company’s events, documents or press releases, please subscribe for investor alerts here.